1.18
price down icon16.90%   -0.24
after-market 시간 외 거래: 1.15 -0.03 -2.54%
loading
전일 마감가:
$1.42
열려 있는:
$1.26
하루 거래량:
2.15M
Relative Volume:
1.41
시가총액:
$7.71M
수익:
-
순이익/손실:
$-11.27M
주가수익비율:
-0.0551
EPS:
-21.4132
순현금흐름:
$-9.40M
1주 성능:
-4.84%
1개월 성능:
+1.62%
6개월 성능:
-24.36%
1년 성능:
-80.85%
1일 변동 폭
Value
$1.18
$1.32
1주일 범위
Value
$1.18
$2.37
52주 변동 폭
Value
$1.00
$6.666

Dermata Therapeutics Inc Stock (DRMA) Company Profile

Name
명칭
Dermata Therapeutics Inc
Name
전화
(858)-223-0882
Name
주소
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Name
직원
0
Name
트위터
Name
다음 수익 날짜
2024-08-15
Name
최신 SEC 제출 서류
Name
DRMA's Discussions on Twitter

DRMA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
DRMA
Dermata Therapeutics Inc
1.18 7.71M 0 -11.27M -9.40M -21.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Dermata Therapeutics Inc 주식(DRMA)의 최신 뉴스

pulisher
Mar 28, 2025

Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus.com

Mar 28, 2025
pulisher
Mar 28, 2025

Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com newswire

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - StockTitan

Mar 27, 2025
pulisher
Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Benzinga India

Mar 27, 2025
pulisher
Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains - Stocks Telegraph

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata shares rise on positive acne treatment trial results By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata's XYNGARI(TM) Phase 3 Trial Topline Data Meets All Primary Endpoints - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

XYNGARI shows promise in Phase 3 acne trial - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial - StockTitan

Mar 27, 2025
pulisher
Mar 25, 2025

Dermata Therapeutics Faces Nasdaq Delisting Notice By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Dermata Therapeutics Faces Nasdaq Delisting Notice - Investing.com

Mar 25, 2025
pulisher
Mar 17, 2025

Dermata Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan

Mar 17, 2025
pulisher
Mar 12, 2025

Stocks Rally as US Consumer Prices Cool - The Globe and Mail

Mar 12, 2025
pulisher
Mar 12, 2025

Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart

Mar 12, 2025
pulisher
Mar 12, 2025

Acne Market on Track for Major Expansion by 2032, According - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne - openPR

Mar 11, 2025
pulisher
Mar 11, 2025

Tesla Stock is OversoldIs Now the Time to Be Brave? - The Globe and Mail

Mar 11, 2025
pulisher
Mar 10, 2025

Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) Head-To-Head Comparison - Defense World

Mar 10, 2025
pulisher
Mar 04, 2025

Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Dermata Therapeutics announces last patient visit in Phase 3 acne trial - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne - PR Newswire

Mar 04, 2025
pulisher
Mar 03, 2025

Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

Papulopustular Rosacea Clinical and Non-Clinical Studies, Key - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis - MSN

Mar 03, 2025
pulisher
Feb 28, 2025

Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga

Feb 28, 2025
pulisher
Feb 25, 2025

DRMADermata Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis - ACCESS Newswire

Feb 25, 2025
pulisher
Feb 16, 2025

Dermata Therapeutics announces $2.55M private offering - MSN

Feb 16, 2025
pulisher
Feb 12, 2025

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire

Feb 12, 2025
pulisher
Feb 07, 2025

Crown Labs completes acquisition of Revance Therapeutics By Investing.com - Investing.com Nigeria

Feb 07, 2025
pulisher
Feb 06, 2025

Crown Labs completes acquisition of Revance Therapeutics - Investing.com India

Feb 06, 2025
pulisher
Jan 31, 2025

Dermata to Present on BioPub on January 31, 2025 - ACCESS Newswire

Jan 31, 2025
pulisher
Jan 29, 2025

Dermata Unveils Game-Changing Skin Disease Treatment Progress: CEO Reveals What's Next - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

Acne Vulgaris Market Expected to rise, 2034 | Pelthos - openPR

Jan 29, 2025
pulisher
Jan 28, 2025

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment - ACCESS Newswire

Jan 28, 2025
pulisher
Jan 27, 2025

Dermata Therapeutics Signs Clinical Trial Collaboration Agreement with Revance Therapeutics for Topical Treatment StudyDermata Therapeutics, Inc. (NASDAQ: DRMA) revealed in an 8-K filing that on January 17, 2025, the company entered into a Clinical T - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Dermata Therapeutics Announces Private Placement of $2.4 Million in Securities SAN DIEGO, CA – Dermata Therapeutics, Inc. (NASDAQ: DRMA) disclosed in a filing on January 21, 2025, that it has entered into a securities purchase agreement for a private - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 24, 2025

Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 24, 2025

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 24, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Jan 24, 2025
pulisher
Jan 23, 2025

Dermata Therapeutics secures $2.55 million in private placement - MSN

Jan 23, 2025

Dermata Therapeutics Inc (DRMA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
자본화:     |  볼륨(24시간):